Clinical Trial

SIRT and Peri-immunotherapy : a New Concept

Study acronym: IMSIRT
Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated May 14, 2025 (before its estimated July 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
The combination of selective internal radiation therapy (SIRT) with immunotherapy represents an innovative and potentially highly effective therapeutic strategy for the treatment of advanced-stage hepatocellular carcinoma (BCLC stage B or C). Although promising results have been observed in preliminary clinical trials, further research is needed to better understand the underlying mechanisms, optimize treatment protocols, and confirm the long-term efficacy and safety of this combined approach
Trial Details
NCT Number NCT06971237
Lead Sponsor Assistance Publique - Hôpitaux de Paris
Conditions Advanced Hepatocellular Carcinoma (HCC), Classified as BCLC Stage B or C, Treated With a Combination of Selective Internal Radiation Therapy
Enrollment 60 participants
Start Date 2025-06-01
Primary Completion 2026-07-01 (estimated)
Study Completion 2026-07-01 (estimated)
Updated on ClinicalTrials.gov 2025-05-14